Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.60 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TACR2 | P21452 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | FDPS | P14324 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5905154 | 0.99 | POLB (0.59) | POLBPDE4BPDE3AALDH1A1KDM4E | |
| SCHEMBL3134563 | 0.94 | POLB (0.60) | POLBPDE4BPDE3AALDH1A1KDM4E | |
| SCHEMBL5905248 | 0.93 | POLB (0.59) | POLBPDE4BPDE3AALDH1A1KDM4E | |
| SCHEMBL4944263 | 0.90 | ALDH1A1 (0.58) | POLBPDE4BPDE3AALDH1A1KDM4E | |
| SCHEMBL13677870 | 0.88 | FDPS (0.51) | POLBPDE4BPDE3AALDH1A1KDM4E | |
| SCHEMBL8845986 | 0.86 | PDE4B (0.49) | POLBPDE4BPDE3AALDH1A1PDE4D | |
| SCHEMBL5905463 | 0.85 | PDE4B (0.48) | POLBPDE4BPDE3AALDH1A1HPGD | |
| SCHEMBL70835 | 0.84 | ALDH1A1 (0.64) | PDE4BPDE3AALDH1A1PDE4DPDE4A | |
| SCHEMBL29808190 | 0.84 | ALDH1A1 (0.64) | PDE4BPDE3AALDH1A1PDE4DPDE4A | |
| SCHEMBL7560477 | 0.84 | ALDH1A1 (0.64) | PDE4BPDE3AALDH1A1PDE4DPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2157084-B1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | KOWA CO (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-8106053-B2 | 5-phenyl-3-pyridazinone derivative | KOWA COMPANY, LTD. | 2012-01-31 | — | — | US | disclosed |
| US-20100197698-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| EP-2157084-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-02-24 | — | — | EP | disclosed |
| EP-1468991-B1 | Imides as PDE III, PDE IV and TNF inhibitors | CELGENE CORP (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20060264477-A1 | Methods of using cyclic amides | MULLER GEORGE W | 2006-11-23 | — | — | US | disclosed |
| US-7081464-B2 | Topical compositions of cyclic amides as immunotherapeutic agents | CELGENE CORPORATION (US) | 2006-07-25 | — | — | US | disclosed |
| US-20060003979-A1 | Topical compositions of cyclic amides as immunotherapeutic agents | CELGENE CORPORATION | 2006-01-05 | — | — | US | disclosed |
| US-20050096355-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2005-05-05 | — | — | US | disclosed |
| EP-1468991-A1 | Imides as PDE III, PDE IV and TNF inhibitors | CELGENE CORPORATION (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030114516-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2003-06-19 | — | — | US | disclosed |
| US-6518281-B2 | Heterocyclic amides/imides as inhibitors of tumor necrosis factor alpha and nuclear factor kappa B and phosphodi-esterases III and IV; used to combat cachexia, endotoxic shock, retrovirus replication and asthma; antiinflammatory | CELGENE CORPORATION | 2003-02-11 | — | — | US | disclosed |
| CN-1092640-C | Imides as PDE III, PDE IV and TNF inhibitors | CELGENE CORP (US) | 2002-10-16 | — | — | CN | disclosed |
| US-20020002188-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2002-01-03 | — | — | US | disclosed |
| US-6180644-B1 | TUMOR NECROSIS FACTOR INHIBITOR; ANTIINFLAMMATORY AGENT | CELGENE CORPORATION | 2001-01-30 | — | — | US | disclosed |
| US-5968945-A | Immunotherapeutic agents | CELGENE CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| CN-1206405-A | Imides as PDE III, PDE IV and TNF inhibitors | CELGENE CORP (US) | 1999-01-27 | — | — | CN | disclosed |
| EP-0874819-A1 | IMIDES AS PDE III, PDE IV AND TNF INHIBITORS | CELGENE CORPORATION (US) | 1998-11-04 | — | — | EP | disclosed |
| US-5728844-A | INHIBITORS OF TUMOR NECROSIS AND PHOSPHODIESTERASE | CELGENE CORPORATION (US) | 1998-03-17 | — | — | US | disclosed |
| WO-1997023457-A1 | IMIDES AS PDE III, PDE IV AND TNF INHIBITORS | CELGENE CORPORATION (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197698-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | SERPINE1, MMP1, PLAT | POLB 2980/4885PDE4B 1932/4885PDE3A 334/4885 |
| US-20050096355-A1 | Novel immunotherapeutic agents | STING1, RNASE1, CGAS | POLB 420/4885PDE4B 15/4885PDE3A 32/4885 |
| US-20020002188-A1 | Novel immunotherapeutic agents | STING1, RNASE1, CGAS | POLB 554/4885PDE4B 13/4885PDE3A 33/4885 |
| US-20030114516-A1 | Novel immunotherapeutic agents | STING1, RNASE1, CGAS | POLB 554/4885PDE4B 13/4885PDE3A 33/4885 |
| US-20060003979-A1 | Topical compositions of cyclic amides as immunotherapeutic agents | TSLP, STING1, CGAS | POLB 107/4885PDE4B 21/4885PDE3A 22/4885 |
| US-20060264477-A1 | Methods of using cyclic amides | RNASE1, RNGTT, CGAS | POLB 112/4885PDE4B 10/4885PDE3A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.